Evidence map›Paper›PMID 14581175›Full record

ArticleBritish journal of pharmacology2003

ATP analogues with modified phosphate chains and their selectivity for rat P2X2 and P2X2/3 receptors.

Valeria Spelta, Abdelaziz Mekhalfia, Dominik Rejman, Mark Thompson, G Michael Blackburn, R Alan North

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 33 citations in OpenAlex.

  1. Synthesis ofTetrahedron letters · 2015
    Article
  2. Heteromeric assembly of P2X subunits.Frontiers in cellular neuroscience · 2013
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Agonists and antagonists for P2 receptors.Novartis Foundation symposium · 2006
    Review
  14. Article
  15. Purine and purinergic receptors.Brain and neuroscience advances
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Valeria SpeltaInstitute of Molecular Physiology, University of Sheffield, Sheffield S10 2TN.
Abdelaziz Mekhalfia
Dominik Rejman
Mark Thompson
G Michael Blackburn
R Alan North
University of Sheffield · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

1. Heteromeric P2X2/3 receptors are much more sensitive than homomeric P2X2 receptors to alphabeta-methylene-ATP, and this ATP analogue is widely used to discriminate the two receptors on sensory neurons and other cells. 2. We sought to determine the structural basis for this selectivity by synthesising ADP and ATP analogues in which the alphabeta and/or betagamma oxygen atoms were replaced by other moieties (including -CH2-, -CHF-, -CHCl-, -CHBr-, -CF2-, -CCl2-, -CBr2-, -CHSO3-, -CHPO3-, -CFPO3-, -CClPO3-, -CH2-CH2-, C triple bond C, -NH-, -CHCOOH-). 3. We tested their actions as agonists or antagonists by whole-cell recording from human embryonic kidney cells expressing P2X2 subunits alone (homomeric P2X2 receptors), or cells expressing both P2X2 and P2X3 subunits, in which the current through heteromeric P2X2/3 receptors was isolated. 4. ADP analogues had no agonist or antagonist effect at either P2X2 or P2X2/3 receptors. All the ATP analogues tested were without agonist or antagonist activity at homomeric P2X2 receptors, except betagamma-difluoromethylene-ATP, which was a weak agonist. 5. At P2X2/3 receptors, betagamma-imido-ATP, betagamma-methylene-ATP, and betagamma-acetylene-ATP were weak agonists, whereas alphabeta,betagamma- and betagamma,gammadelta-bismethylene-AP4 were potent full agonists. betagamma-Carboxymethylene-ATP and betagamma-chlorophosphonomethylene-ATP were weak antagonists at P2X2/3 receptors (IC50 about 10 microm). 6. The results indicate (a). that the homomeric P2X2 receptor presents very stringent structural requirements with respect to its activation by ATP; (b). that the heteromeric P2X2/3 receptor is much more tolerant of alphabeta and betagamma substitution; and (c). that a P2X2/3-selective antagonist can be obtained by introduction of additional negativity at the betagamma-methylene.

Indexed as

Adenosine DiphosphateAdenosine TriphosphateAnimalsCell LineChild, PreschoolDimerizationDiphosphatesDose-Response Relationship, DrugHumansMembrane PotentialsPolyphosphatesPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsRatsReceptors, Purinergic P2Receptors, Purinergic P2X2Adenosine DiphosphateAdenosine TriphosphateDiphosphatesP2RX2 protein, humanP2rx2 protein, ratP2RX3 protein, humanP2rx3 protein, ratPolyphosphatesPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsReceptors, Purinergic P2Receptors, Purinergic P2X2Receptors, Purinergic P2X3triphosphoric acid

Identifiers

PMID14581175
PMCPMC1574118
OpenAlexW2048562538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.